These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7986764)

  • 1. Population and Bayesian pharmacokinetics in oncology.
    Ranson MR; Scarffe JH
    Clin Oncol (R Coll Radiol); 1994; 6(4):254-60. PubMed ID: 7986764
    [No Abstract]   [Full Text] [Related]  

  • 2. [Contribution of computers to pharmacokinetics, Bayesian approach and population pharmacokinetics].
    Hecquet B
    Bull Cancer; 1995 Dec; 82 Suppl 5():607s-611s. PubMed ID: 8680074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
    Zhou L; Higashimori M; Shen K; Zhang Z; Sheng J; Xu H; Horiuchi M; Ichikawa K; Al-Huniti N; Zhou D
    Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
    [No Abstract]   [Full Text] [Related]  

  • 4. A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
    Zheng W; Zhao Y; Lu Y; Miao H; Liu H
    J Biopharm Stat; 2016; 26(2):339-51. PubMed ID: 25629564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and population pharmacokinetics in pediatric oncology.
    Sassen SDT; Zwaan CM; van der Sluis IM; Mathôt RAA
    Pediatr Blood Cancer; 2020 Apr; 67(4):e28132. PubMed ID: 31876123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs.
    Cardoso E; Csajka C; Schneider MP; Widmer N
    Clin Pharmacokinet; 2018 Jan; 57(1):1-6. PubMed ID: 28634655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of pharmacokinetic research in oncology.
    Siderov J; Brien JE; Morgan DJ; Zalcberg J; Cosolo W
    Br J Cancer; 1995 Sep; 72(3):792-4. PubMed ID: 7669597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-toxicity models in oncology.
    Adamina M; Joerger M
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):201-11. PubMed ID: 21241201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.
    Yuan Y; Hess KR; Hilsenbeck SG; Gilbert MR
    Clin Cancer Res; 2016 Sep; 22(17):4291-301. PubMed ID: 27407096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adaptive dose-finding approach for correlated bivariate binary and continuous outcomes in phase I oncology trials.
    Hirakawa A
    Stat Med; 2012 Mar; 31(6):516-32. PubMed ID: 22108785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
    Takimoto CH
    Eur J Cancer; 2009 Sep; 45 Suppl 1():436-8. PubMed ID: 19775662
    [No Abstract]   [Full Text] [Related]  

  • 13. Adaptive design improvements in the continual reassessment method for phase I studies.
    Heyd JM; Carlin BP
    Stat Med; 1999 Jun; 18(11):1307-21. PubMed ID: 10399198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.
    Lin R; Yin G
    Stat Med; 2017 Nov; 36(26):4106-4120. PubMed ID: 28786138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology.
    Park K
    Yonsei Med J; 2017 Jan; 58(1):1-8. PubMed ID: 27873489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic modelling--a prelude to therapeutic drug monitoring for all cancer patients?
    Judson IR
    Eur J Cancer; 1995 Oct; 31A(11):1733-5. PubMed ID: 8541090
    [No Abstract]   [Full Text] [Related]  

  • 17. Detection and management of oncology drug interactions: Can we do better?
    Chan A; Yap KY
    Maturitas; 2010 Mar; 65(3):181-2. PubMed ID: 20036470
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology.
    Takeda K; Komatsu K; Morita S
    Pharm Stat; 2018 Nov; 17(6):725-733. PubMed ID: 30066356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimalism in oncology.
    The Lancet Oncology
    Lancet Oncol; 2018 May; 19(5):579. PubMed ID: 29726372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.